What outcome data do you view as most impactful to make treatment decisions regarding the use of PARP inhibitors in later line or recurrent ovarian cancer?
Given the crossover that occurred in the various clinical trials and the potential for prolonged disease duration, how do you integrate OS, PFS, treatment free intervals, quality of life, or total cytotoxic chemotherapy exposure when considering treatment options?
Community PollStarted
What outcome data do you view as most impactful to make treatment decisions regarding the use of PARP inhibitors in later line or recurrent ovarian cancer?
29 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Gynecologic Oncology · Icahn School of Medicine at Mount Sinai
Answered on
The crossover makes the OS data very hard, if not impossible, to interpret. The findings were not that parps for platinum sensitive maintenance for non-BRCAm were detrimental -- it was that they did not seem to show OS benefit. Certainly, treatment free intervals and quality of life are extremely im...
Join for free or sign in to see the full answer